Catalyst Pharmaceuticals Announces Topline Results From Two-Part Phase 1 Clinical Study Of Vamorolone In Healthy Adult Volunteers

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

Italian pharmaceutical company Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for approximately $4.1 billion USD ($3.5 billion EUR). The deal strengthens Angelini Pharma's global presence in brain health and rare diseases while expanding into the U.S. market. Blackstone will invest €1 billion in preferred equity, and CDP Equity will acquire a 23.5% stake in Angelini Pharma for approximately €1 billion.

8-K filing — CATALYST PHARMACEUTICALS, INC. (CPRX)

Filed: 2026-07-16 AccNo: 0001193125-26-304984 Size: 312 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026